Key result
Surgery (HR 0.53; 95% CI 0.36-0.77) and chemotherapy (HR 0.51; 95% CI 0.36-0.73) were significantly associated with improved overall survival in patients with pulmonary carcinosarcoma.
Why the study?
Pulmonary carcinosarcoma is a rare neoplasm, prompting exploration of its clinicopathological characteristics and survival outcomes.
What are the clinicopathological characteristics and survival outcomes of pulmonary carcinosarcoma, and how do treatments like surgery and chemotherapy affect overall survival?
Cohort
Yes
What are the clinicopathological characteristics and survival outcomes of pulmonary carcinosarcoma, and how do treatments like surgery and chemotherapy affect overall survival?
In patients with pulmonary carcinosarcoma, surgery and chemotherapy are associated with improved overall survival, though pneumonectomy is associated with poorer outcomes in elderly patients.
OBJECTIVES: Pulmonary carcinosarcoma (PCS) is a rare neoplasm. This study explored the clinicopathological characteristics and survival outcomes of PCS. METHODS: The Surveillance, Epidemiology and End Results (SEER) database (1988-2014) was queried for PCS. Overall survival (OS) was evaluated by multivariable Cox regression and nomograms were constructed to predict 3-year OS for PCS. Prognostic performance was evaluated using concordance index and area under the curve analysis. In M0 surgically treated patients, interaction assessments were performed using likelihood ratio tests. Subgroup analysis was performed according to patient age. The clinical features of PCSs were further compared to other non-small-cell lung cancers (NSCLCs). RESULTS: Multivariable analysis identified age [hazard ratio (HR) 1.03, 95% confidence interval (CI) 1.01-1.04], surgery (HR 0.53, 95% CI 0.36-0.77) and chemotherapy (HR 0.51, 95% CI 0.36-0.73) as significantly associated with OS. The nomogram had a concordance index of 0.747 and an area under the curve of 0.803. The association between age and OS was stronger in those receiving pneumonectomy (P = 0.04 for interactions) compared to those that did not (HR 5.14, 95% CI 1.64-16.07), and was associated with a poorer outcome compared to lobectomy amongst the elderly (age ≥ 70 years). Patients with PCS were more likely to receive surgical treatment and had lower lymphatic metastasis compared to adenocarcinoma, squamous cell carcinoma and large cell carcinoma (all P < 0.05). CONCLUSIONS: PCS had unique clinical features compared to common types of NSCLCs in terms of lymphatic invasion and surgical treatment. Pneumonectomy was associated with poorer survival in elderly patients.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2019) conducted a cohort in Pulmonary carcinosarcoma. Surgery vs. No surgery was evaluated on Overall survival (HR 0.53, 95% CI 0.36-0.77). Surgery (HR 0.53; 95% CI 0.36-0.77) and chemotherapy (HR 0.51; 95% CI 0.36-0.73) were significantly associated with improved overall survival in patients with pulmonary carcinosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: